Contribution of defective von Willebrand factor (VWF) multimerization, regulated storage, and secretion to type 1C von Willebrand disease (VWD)

被引：0
作者：
Jakab, D. A. [1 ]
Jacobi, P. M. [1 ]
Haberichter, S. L. [1 ,2 ]
机构：
[1] BloodCtr Wisconsin, Milwaukee, WI USA
[2] Med Coll Wisconsin, Milwaukee, WI 53226 USA
来源：
JOURNAL OF THROMBOSIS AND HAEMOSTASIS | 2014年 / 12卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
VWF12
引用
收藏
页码：94 / 94
页数：1
相关论文
共 50 条
  • [31] A novel von Willebrand disease-causing mutation (Arg273Trp) in the von Willebrand factor propeptide that results in defective multimerization and secretion
    Allen, S
    Abuzenadah, AM
    Hinks, J
    Blagg, JL
    Gursel, T
    Ingerslev, J
    Goodeve, AC
    Peake, IR
    Daly, ME
    BLOOD, 2000, 96 (02) : 560 - 568
  • [32] Expression studies of eight missense mutations spread through out the von Willebrand factor (vwf) in type 3 von willebrand Disease (VWD) patients
    Baronciani, L.
    Solimando, M.
    La Marca, S.
    Cozzi, G.
    Stufano, F.
    Canciani, M. T.
    Federici, A. B.
    Peyvandi, F.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2011, 9 : 912 - 912
  • [33] Type 2M von Willebrand disease variant characterized by abnormal von Willebrand factor multimerization
    Casonato, A
    Pontara, E
    Sartorello, F
    Bertomoro, A
    Durante, C
    Girolami, A
    JOURNAL OF LABORATORY AND CLINICAL MEDICINE, 2001, 137 (01): : 70 - 76
  • [34] Type 2A (IIH) von Willebrand disease is due to mutations that affect von Willebrand factor multimerization
    Baronciani, L.
    Federici, A. B.
    Punzo, M.
    Solimando, M.
    Cozzi, G.
    La Marca, S.
    Rubini, V.
    Canciani, M. T.
    Mannucci, P. M.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 (07) : 1114 - 1122
  • [35] PHARMACOKINETICS (PK) OF VON WILLEBRAND FACTOR (VWF) IN PATIENTS WITH VON WILLEBRAND DISEASE (VWD) AFTER TREATMENT WITH RECOMBINANT VWF OR PLASMA-DERIVED VWF CONCENTRATE.
    Wang, Y.
    Marier, J.
    Vasilinin, G.
    Berthoz, F. Truong
    Azen, G.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2021, 109 : S36 - S37
  • [36] Critical Importance Of VWF Propeptide (VWFpp) In The Diagnosis Of Type 1 Von Willebrand Disease (VWD)
    Haberichter, Sandra L.
    Christopherson, Pamela A.
    Flood, Veronica H.
    Gill, Joan Cox
    Bellissimo, Daniel B.
    Friedman, Kenneth D.
    Montgomery, Robert R.
    BLOOD, 2013, 122 (21)
  • [37] Von Willebrand disease: Assessing platelet von Willebrand factor and other variables in patients with presumed type 1 VWD.
    Konkle, BA
    Tarng, HI
    BLOOD, 2002, 100 (11) : 494A - 494A
  • [38] Evaluating Performance of Contemporary and Historical von Willebrand Factor (VWF) Assays in the Laboratory Identification of von Willebrand Disease (VWD): The Australasian Experience
    Favaloro, Emmanuel J.
    Dean, Elysse
    Arunachalam, Sandya
    SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2022, 48 (06) : 711 - 731
  • [39] Mutations in the D1 Domain Inhibit Propeptide-Dependent Multimerization, Trafficking and Regulated Secretion of Von Willebrand Factor in VWD
    Yin, Jie
    Ma, Zhenni
    Su, Jian
    Zhao, Xiaojuan
    Wang, Zhaoyue
    Yu, Ziqiang
    Ouyang, Wanyan
    Bai, Xia
    Ruan, Changgeng
    BLOOD, 2014, 124 (21)
  • [40] Von Willebrand factor contribution to pathophysiology outside of von Willebrand disease
    Mojiri, Anahita
    Alavi, Parnian
    Jahroudi, Nadia
    MICROCIRCULATION, 2019, 26 (04)
12345